Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 2282

Drug Profile

REC 2282

Alternative Names: AR-42; NSC-D736012; OSU-HDAC42; REC-2282

Latest Information Update: 10 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics; Celgene Corporation; Ohio State University Comprehensive Cancer Center; Recursion Pharmaceuticals; Virginia Commonwealth University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Deacetylase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningioma; Neurilemmoma; Neurofibromatosis 2
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurofibromatosis 2
  • No development reported Acute myeloid leukaemia
  • Discontinued Bladder cancer; Chronic lymphocytic leukaemia; Lymphoma; Meningioma; Multiple myeloma; Neurilemmoma; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 04 Jan 2019 OSU-HDAC42 licensed to Recursion worldwide
  • 04 Jan 2019 Preclinical trials in Neurofibromatosis 2 in USA
  • 04 Jan 2019 Recursion plans a human proof of concept trial for neurofibromatoses type 2
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top